Return On Equity
-135%
Trailing 12 months · Through 30 Sep 2025
YoY relative change: -63%
Evoke Pharma Inc financial metrics
Period Q3 2025 · Filed 13 Nov 2025
Key metrics snapshot
Return On Assets
-35%
Trailing 12 months · Through 30 Sep 2025
YoY relative change: -40%
Operating Margin
-36%
Trailing 12 months · Through 30 Sep 2025
YoY relative change: -47%
Current Ratio
1.27x
Period-end balance · Through 30 Sep 2025
YoY relative change: -12%
Quick Ratio
1.22x
Period-end balance · Through 30 Sep 2025
YoY relative change: -12%
Debt-to-equity
2.18x
Period-end balance · Through 30 Sep 2025
YoY relative change: -54%
Revenues YoY
67%
Trailing 12 months · Through 30 Sep 2025
NetIncomeLoss YoY
19%
Trailing 12 months · Through 30 Sep 2025
Profitability
| Metric | Latest value | YoY relative change |
|---|---|---|
| Return On Equity |
-135%
Trailing 12 months · 30 Sep 2025
|
-63% |
| Return On Assets |
-35%
Trailing 12 months · 30 Sep 2025
|
-40% |
| Operating Margin |
-36%
Trailing 12 months · 30 Sep 2025
|
-47% |
Financial Health
| Metric | Latest value | YoY relative change |
|---|---|---|
| Current Ratio |
1.27x
Period-end balance · 30 Sep 2025
|
-12% |
| Quick Ratio |
1.22x
Period-end balance · 30 Sep 2025
|
-12% |
| Debt-to-equity |
2.18x
Period-end balance · 30 Sep 2025
|
-54% |
Growth
| Metric | Latest value | YoY relative change |
|---|---|---|
| Revenues YoY |
67%
Trailing 12 months · 30 Sep 2025
|
|
| NetIncomeLoss YoY |
19%
Trailing 12 months · 30 Sep 2025
|
Share Metrics
| Metric | Latest value | YoY relative change |
|---|---|---|
| Entity Common Stock, Shares Outstanding |
1,722,409
Period-end balance · 06 Nov 2025
|
+16% |
| Common Stock, Shares, Outstanding |
1,722,409
Period-end balance · 30 Sep 2025
|
+92% |
| Common Stock, Value, Issued |
$172
Period-end balance · 30 Sep 2025
|
+93% |
| Weighted Average Number of Shares Outstanding, Basic |
2,557,408
Reported period · 30 Sep 2025
|
+83% |
| Weighted Average Number of Shares Outstanding, Diluted |
2,557,408
Reported period · 30 Sep 2025
|
+83% |
Supporting Metrics
These supporting metrics stay fully source-backed for deeper research. Scan the latest value and reported period first, then open a metric page when you need the full filing trail.
| Metric | Latest value | YoY relative change |
|---|---|---|
| Assets |
$15,649,433
Period-end balance · 30 Sep 2025
|
+11% |
| Assets, Current |
$15,536,407
Period-end balance · 30 Sep 2025
|
+11% |
| Cash and Cash Equivalents, at Carrying Value |
$11,576,010
Period-end balance · 30 Sep 2025
|
+2.1% |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents |
$11,576,010
Period-end balance · 30 Sep 2025
|
+2.1% |
| Common Stock, Par or Stated Value Per Share |
0
Period-end balance · 30 Sep 2025
|
0% |
| Common Stock, Shares Authorized |
100,000,000
Period-end balance · 30 Sep 2025
|
0% |
| Common Stock, Shares, Issued |
1,722,409
Period-end balance · 30 Sep 2025
|
+92% |
| Earnings Per Share, Basic |
0
Trailing 12 months · 30 Sep 2025
|
+98% |
| Earnings Per Share, Diluted |
0
Trailing 12 months · 30 Sep 2025
|
+98% |
| Employee-related Liabilities, Current |
$770,915
Period-end balance · 30 Sep 2025
|
+31% |
| Interest Expense |
$500,001
Trailing 12 months · 30 Sep 2025
|
-0.27% |
| Inventory, Net |
$599,908
Period-end balance · 30 Sep 2025
|
+22% |
| Lessee, Operating Lease, Liability, to be Paid |
$120,516
Period-end balance · 30 Sep 2025
|
|
| Lessee, Operating Lease, Liability, to be Paid, Year One |
$80,207
Period-end balance · 30 Sep 2025
|
|
| Lessee, Operating Lease, Liability, to be Paid, Year Two |
$20,551
Period-end balance · 30 Sep 2025
|
|
| Lessee, Operating Lease, Liability, Undiscounted Excess Amount |
$8,167
Period-end balance · 30 Sep 2025
|
|
| Liabilities |
$12,287,197
Period-end balance · 30 Sep 2025
|
+26% |
| Liabilities and Equity |
$15,649,433
Period-end balance · 30 Sep 2025
|
+11% |
| Liabilities, Current |
$12,240,816
Period-end balance · 30 Sep 2025
|
+25% |
| Operating Income (Loss) |
-$5,191,981
Trailing 12 months · 30 Sep 2025
|
+12% |
| Operating Lease, Liability |
$112,349
Period-end balance · 30 Sep 2025
|
|
| Operating Lease, Liability, Current |
$65,968
Period-end balance · 30 Sep 2025
|
|
| Operating Lease, Liability, Noncurrent |
$46,381
Period-end balance · 30 Sep 2025
|
|
| Operating Lease, Payments |
$70,803
Trailing 12 months · 30 Sep 2025
|
-15% |
| Operating Lease, Right-of-Use Asset |
$106,714
Period-end balance · 30 Sep 2025
|
|
| Other Assets, Current |
$33,708
Period-end balance · 30 Sep 2025
|
-7.4% |
| Other Assets, Noncurrent |
$6,312
Period-end balance · 30 Sep 2025
|
|
| Preferred Stock, Par or Stated Value Per Share |
0
Period-end balance · 30 Sep 2025
|
0% |
| Preferred Stock, Shares Authorized |
5,000,000
Period-end balance · 30 Sep 2025
|
0% |
| Preferred Stock, Shares Issued |
0
Period-end balance · 30 Sep 2025
|
|
| Preferred Stock, Shares Outstanding |
0
Period-end balance · 30 Sep 2025
|
|
| Retained Earnings (Accumulated Deficit) |
-$132,824,994
Period-end balance · 30 Sep 2025
|
-4.1% |
| Revenue from Contract with Customer, Excluding Assessed Tax |
$14,424,652
Trailing 12 months · 30 Sep 2025
|
+67% |
| Share-based Payment Arrangement, Noncash Expense |
$554,620
Trailing 12 months · 30 Sep 2025
|
-30% |
| Stockholders' Equity Attributable to Parent |
$3,362,236
Period-end balance · 30 Sep 2025
|
-23% |
Comparisons, sources and research notes
Sources and sharing
Evoke Pharma Inc Financial Facts
- Context
- Latest metrics period: Q3 2025
- Latest reported value
- Return On Equity -135%
Based on company facts extracted from SEC 10-Q/10-K XBRL filings where available. Open metric pages to inspect the reported history.
Tracking and update notes
Why revisit this company facts page
Company facts change as new 10-Q and 10-K filings update the latest reported period, headline values, and cross-company comparison context.
- Latest source-backed update
- Latest metrics period Q3 2025
- Why come back
- Use the next filing cycle to compare new facts against this baseline and then verify the detailed metric history.
- Current latest metrics period: Q3 2025.
- Most recent SEC facts end date on this page: 06 Nov 2025.
- Save this filer to return when the next filing-backed metric period changes the picture.
Freshness comes from the latest SEC company facts period available for this filer and the linked metric history pages.
Latest update
Latest update for Evoke Pharma Inc
Latest financial period: Q3 2025. Reopen this facts page to verify the newest reported period against the prior baseline.
Update date
13 Nov 2025
Page type
Company facts
Latest period
Q3 2025
SEC-backed company facts were refreshed from filings filed on 13 Nov 2025.
Benchmark Context
How Return On Equity compares
Return On Equity is down about 63% versus the comparable prior period.
Compared with
Compared with Evoke Pharma Inc's recent history first. Same-industry peer context appears only when enough SEC-backed benchmark coverage exists.
Why this is notable
Return On Equity already has a self-history signal here, but same-industry benchmark context waits until the benchmark sample is strong enough.
- Latest comparable period on this page: Q3 2025.
- Peer context will appear when enough companies report a comparable value for this metric.
- Open the metric history first if you want to verify the exact period-to-period change.
Industry benchmark context uses SEC-reported values from the same methodology version. Latest periods may differ across companies.
How to read key metrics on this page
These short guides explain what the headline metrics mean, what to compare next, and where to open the live SEC-backed example for this company.
Plain-English Guide
How to read Revenue on this page
Revenue is the sales a company reports from customers before most expenses are subtracted.
Why people care
People start here to understand business scale and whether demand is growing before they ask about margins or cash flow.
How to read it
Check the latest reported period first, then compare the same quarter or year against prior periods so seasonality does not distort the story.
Compare next
Compare revenue with gross profit, operating income, and operating cash flow to see whether sales are turning into healthy economics.
Revenue can jump because of acquisitions, pricing changes, or revenue-recognition rules, and reporting periods may differ across companies.
Open a live SEC-backed example
Plain-English Guide
How to read Net Income on this page
Net income is profit after operating costs, interest, taxes, and other non-operating items.
Why people care
It is the bottom-line profit figure many users recognize first, especially when they want to compare earnings with sales or cash flow.
How to read it
Use the same quarter or fiscal year comparison first, then check operating income or cash flow if the bottom line moved sharply.
Compare next
Compare it with operating income, EPS, and operating cash flow to see whether earnings are broad-based or driven by one-off items.
Net income can swing because of tax, financing, or accounting adjustments, so it is often less comparable than core operating metrics.
Open a live SEC-backed example
Filing notes and source
Key facts
- Evoke Pharma Inc financial facts use SEC filings; any third-party reference is labeled separately.
- Latest metrics period on this page: Q3 2025.
- Headline metric: Return On Equity -135%.
Change
- Return On Equity YoY relative change: -63%.
- Most recent SEC facts end date: 06 Nov 2025.
Research use
- This gives a beginner-friendly first read before you inspect detailed formulas and metric tables.
- Metric cards link to SEC history; a third-party reference may use a different or unverified reporting period.
Evidence
Based on latest 10-Q/10-K
View source filing
Based on company facts extracted from SEC 10-Q/10-K XBRL filings where available. Open company facts to inspect the reported metric history.
Latest financial snapshot (2025-11-06) highlights Return On Equity -134.9%, Return On Assets -35.1%, and Operating Margin -36.0%.
Valuation Snapshot
SEC-only DCF estimate using a normalized free cash flow base, cash, debt, and reported share count when available.
No market comparison
USD inputs only. Cash and complete debt must share the latest balance date. Missing balances are unknown, never zero; equity value and market EV remain unavailable until both are verified.
DCF estimate is unavailable because required valuation inputs are missing.
Missing: Free cash flow.
Input periods, units and SEC sources
Equity value = DCF enterprise value + cash − debt. Cash flow uses matching annual or trailing-12-month periods.
- Operating cash flow: -3,324,527.0 USD · through 2025-09-30 · prior annual + current YTD − prior YTD SEC source SEC source SEC source
- Capital expenditures: unavailable on a verified comparable basis
- Cash and equivalents: 11,576,010.0 USD · through 2025-09-30 SEC source
- Debt: unavailable on a verified comparable basis
Data confidence notes
- Free cash flow unavailable: matching usd annual or trailing-12-month operating cash flow and cash capex are required
- Debt unavailable: no complete usd debt balance at the latest balance date
- Ticker missing for issuer
- Valuation unavailable: free cash flow is missing
Compare This Company Through SEC-backed Metrics
Use these links to compare Evoke Pharma Inc against other SEC filers on the same metric, then verify the company history from the paired facts page.
Revenues YoY
Latest value: 67%
NetIncomeLoss YoY
Latest value: 19%
Financial Quality Score
Transparent 0-100 scoring model based on profitability, financial health, and growth factors.
49.5/100
Caution Confidence high
Return On Equity
-135%
Metric score 0.0/100
Return On Assets
-35%
Metric score 0.0/100
Financial Health
- Current Ratio
- 1.27x
- Quick Ratio
- 1.22x
- Debt to Equity
- 2.18x
Strengths
Current Ratio, Quick Ratio, and Revenues YoY
Watchpoints
Return On Equity, Return On Assets, and Operating Margin
Calculation methodology and other links
How we score
This score is transparent and deterministic. We weight profitability, financial health, and growth metrics, then renormalize weights when SEC data is missing.
| Metric | Weight | V1 threshold |
|---|---|---|
| ROIC | 20 | 5% to 20% |
| ROE | 15 | 8% to 25% |
| ROA | 10 | 2% to 10% |
| Operating Margin | 5 | 5% to 25% |
| Current Ratio | 12 | 1.0x to 2.0x |
| Quick Ratio | 8 | 0.8x to 1.5x |
| Debt to Equity | 10 | 0.3x to 2.0x (lower is better) |
| Revenue YoY | 10 | -10% to +20% |
| Net Income YoY | 10 | -10% to +20% |
How Calculated (standard_v1)
Metrics are computed with a market-consensus convention designed for cross-portal comparability.
- Operating Income / Revenues using matching TTM or quarter periods; basis shown per metric
- Current Assets / Current Liabilities (latest instant quarter)
- (Current Assets - Inventory) / Current Liabilities; fallback: (Cash+Short-Term Investments + Accounts Receivable) / Current Liabilities
- Total Debt / Stockholders Equity (latest instant quarter; shared unit; freshest series)
- TTM Net Income / Average Equity (current quarter + same quarter previous year) / 2
- TTM Net Income / Average Assets (current quarter + same quarter previous year) / 2
- TTM NOPAT / Average Invested Capital, where NOPAT=Operating Income*(1-tax rate), Invested Capital=Equity+Total Debt-Cash & ST Investments
- Revenues YoY using available TTM or quarter comparison; basis shown per metric
- Net Income YoY using available TTM or quarter comparison; basis shown per metric
CIK / security context first